Monthly Archives: November 2011

Accelerated Approvals Could Raise Risks for Patients

By Erik Greb. FDA approved 35 innovative drugs in fiscal 2011, including treatments for hepatitis C, prostate cancer, Hodgkin’s lymphoma, and lupus. This number of approvals is among the highest in the past 10 years, and it reflects the agency’s efforts to hasten patients’ access to new drugs. In the past two years, the agency’s […]
Posted in Guest Blog, Regulatory, Safety | Tagged , , , , | Leave a comment

What Pharma Could Do for Occupy Wall Street

Demonstrators at Zuccotti Park in New York City persevered through the first snow of the season, while reports from other U.S.-based occupations – in Denver, Oakland, Nashville and other cities – are tallying the arrests, which have become increasingly frequent, and forceful. “The whole world is watching,” a chant that gained prominence during anti-war protests […]
Posted in Corporate Responsibility, Events, leadership, Market Access, Strategy | Tagged , | 7 Comments

The Seven-Billion Society: What's In It For Pharma?

On Monday, the world’s population hit the 7 billion mark, repeating a pattern of largely unrestrained growth that has endured for the last century: the world is now adding roughly one billion people every 12 years. The UN Population Fund (UNPF) estimates that, barring some unforeseen demographic or environmental/development shifts, the figure will reach just […]
Posted in Global, healthcare, Op-Ed | Tagged , , , , | 1 Comment

New Coalition Takes on Neglected Tropical Diseases

A new coalition for sharing pharma IP takes aim at the increasing burden of neglected tropical diseases in the developing world. According to the World Health Organization, neglected tropical diseases affect more than one billion of the world’s poorest 2.7 billion people. Many of these diseases, which can cause blindness and other debilitating symptoms, have […]
Posted in Corporate Responsibility, IP | Tagged , , , , , | Leave a comment
  • Categories

  • Meta